NCT05601973 - Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 27, 2023

Primary Completion Date

March 30, 2026

Study Completion Date

September 30, 2026

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Amivantamab

Amivantamab is given at a fixed dose of 1750 mg (if baseline body weight is \<80 kg) or 2100 mg (if baseline body weight is ≥80 kg), i.v. every 3 weeks, until disease progression, or intolerable toxicity.

DRUG

Lazertinib

Lazertinib is given at a dose of 240 mg, orally, once daily. Treatment with lazertinib continues until disease progression or intolerable toxicities.

DRUG

Zirabev

Bevacizumab (Zirabev®) is administered at a dose of 15mg/kg, i.v. every 3 weeks, until disease progression, or intolerable toxicity.

Trial Locations (18)

Unknown

Chu Angers, Angers

Centre Hospitalier d'Avignon, Avignon

Centre Léon Bérard, Lyon

AO SM Misericorida Perugia, Perugia

Netherlands Cancer Institute (NKI), Amsterdam

Hospital Universitario de A Coruña, A Coruña

Hospital Universitario Alicante Dr Balmis ISABIAL, Alicante

ICO Badalona, Badalona

Vall d´Hebron University Hospital VHIO, Barcelona

Hospital Universitario Basurto, Bilbao

Catalan Institute of Oncology, L'Hospitalet de Llobregat

Hospital Universitario Fundación Jiménez Díaz, Madrid

Hospital clínico universitario de Valladolid, Valladolid

Istituto Oncologico della Svizzera Italiana, Bellinzona

Universitätsklinik für Medizinische Onkologie, Inselspital, Bern

Hôpitaux universitaires de Genève (HUG), Geneva

Kantonsspital St. Gallen, Sankt Gallen

The Royal Marsden NHS Foundation Trust, London